US2183521028 - Common Stock
27.19 +0.65 (+2.45%)
After market: 27.19 0 (0%)
CORCEPT THERAPEUTICS INC
NASDAQ:CORT (12/11/2023, 3:30:00 PM)After market: 27.19 0 (0%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. The company is headquartered in Menlo Park, California and currently employs 299 full-time employees. The company went IPO on 2004-04-15. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The firm has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
CORCEPT THERAPEUTICS INC
149 Commonwealth Dr
Menlo Park CALIFORNIA 94025
CEO: Joseph K. Belanoff
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT.
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.
Corcept Therapeutics' Q3 financial results exceed expectations with higher revenue and increased guidance for 2023.
Here you can normally see the latest stock twits on CORT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.